RELMADA THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Other
RELMADA THERAPEUTICS, INC. (RLMD) had Deferred Tax Assets, Tax Deferred Expense, Other of $7.76 million as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2025-03-27
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $7.76M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2024-12-31 | $7.76M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |